tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Van Leent EJ et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. 1998 Arch Dermatol pmid:9681343
Lener EV et al. Successful treatment of erosive lichen planus with topical tacrolimus. 2001 Arch Dermatol pmid:11295919
Neill SM and Lewis FM Vulvovaginal lichen planus: a disease in need of a unified approach. 2008 Arch Dermatol pmid:19015426
Cooper SM et al. Vulvovaginal lichen planus treatment: a survey of current practices. 2008 Arch Dermatol pmid:19015433
Lally A et al. Penile pyoderma gangrenosum treated with topical tacrolimus. 2005 Arch Dermatol pmid:16172330
Passeron T et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. 2004 Arch Dermatol pmid:15381545
Bunker CB et al. Topical tacrolimus, genital lichen sclerosus, and risk of squamous cell carcinoma. 2004 Arch Dermatol pmid:15381566
Ng W and Ikeda S Mount Tsukuba and the origin of tacrolimus. 2009 Arch Dermatol pmid:19289758
Mikhail M et al. Rapid enlargement of a malignant melanoma in a child with vitiligo vulgaris after application of topical tacrolimus. 2008 Arch Dermatol pmid:18427063
Antille C et al. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. 2004 Arch Dermatol pmid:15096374
Allen DM and Esterly NB Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. 2002 Arch Dermatol pmid:12225004
Yeh C et al. Effect of FK506 on functional recovery after facial nerve injury in the rat. 2007 Sep-Oct Arch Facial Plast Surg pmid:17875826
Geramizadeh B et al. Post-transplantation lymphoproliferative disorder after liver transplantation: report of 5 cases among more than 550 liver transplants in Iran. 2010 Arch Iran Med pmid:20804309
Dehghani SM et al. Tacrolimus related hypertrophic cardiomyopathy in liver transplant recipients. 2010 Arch Iran Med pmid:20187665
Rybojad M [Atopic dermatitis]. 2012 Arch Pediatr pmid:22796288
Monchaud C et al. [Long lasting side effects of immunosuppressants in children]. 2007 Arch Pediatr pmid:17442546
Sánchez Ferreiro AV and Muñoz Bellido L [Tacrolimus in the treatment of atopic kerato-conjunctivitis]. 2013 Arch Soc Esp Oftalmol pmid:23886369
Rodríguez-Ausín P et al. Topical tacrolimus 0.03% for the treatment of ocular psoriasis. 2016 Arch Soc Esp Oftalmol pmid:27130870
Fryer JP et al. Bacterial translocation in a large-animal model of small-bowel transplantation. Portal vs systemic venous drainage and the effect of tacrolimus immunosuppression. 1996 Arch Surg pmid:8546583
Harmon JV et al. Experimental short-term immunosuppression after bowel transplantation and donor-specific bone marrow infusion. 2001 Arch Surg pmid:11448397
Echigo Y et al. Effects of cyclosporine and tacrolimus (FK 506) on acute pancreatitis in mice. 1995 Arch Surg pmid:7528496
Freise CE et al. Excellent short-term results with steroid-free maintenance immunosuppression in low-risk simultaneous pancreas-kidney transplantation. 2003 Arch Surg pmid:14557130
Johnson MW et al. Hepatitis C viral infection in liver transplantation. 1996 Arch Surg pmid:8611094
Stötter H and Lotze MT Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. 1991 Arch Surg pmid:1726819
Wen H et al. Characterization of the binding sites for the interactions between FKBP12 and intracellular calcium release channels. 2012 Arch. Biochem. Biophys. pmid:22100703
Vincent SH et al. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. 1992 Arch. Biochem. Biophys. pmid:1373595
Yin M and Ochs RS Mechanism for the paradoxical inhibition and stimulation of calcineurin by the immunosuppresive drug tacrolimus (FK506). 2003 Arch. Biochem. Biophys. pmid:14592464
Salowe SP and Hermes JD Competitive and slow-binding inhibition of calcineurin by drug x immunophilin complexes. 1998 Arch. Biochem. Biophys. pmid:9675023
Tomono M et al. Inhibitors of calcineurin block expression of cyclins A and E induced by fibroblast growth factor in Swiss 3T3 fibroblasts. 1998 Arch. Biochem. Biophys. pmid:9606972
Kakegawa T et al. Rapamycin induces binding activity to the terminal oligopyrimidine tract of ribosomal protein mRNA in rats. 2002 Arch. Biochem. Biophys. pmid:12051685
Mukerjee N et al. Caspase-mediated proteolytic activation of calcineurin in thapsigargin-mediated apoptosis in SH-SY5Y neuroblastoma cells. 2000 Arch. Biochem. Biophys. pmid:10898953
Borro JM et al. Long-term success of combined kidney-lung transplantation in a patient with cystic fibrosis. 2013 Arch. Bronconeumol. pmid:23427867
Reig Mezquida JP et al. Thrombotic microangiopathy associated with tacrolimus in lung transplantation. 2015 Arch. Bronconeumol. pmid:25138798
Zurbano F et al. Maternity and lung transplantation: cases in Spain. 2012 Arch. Bronconeumol. pmid:22771003
Nishimuta K and Ito Y Effects of metronidazole and tinidazole ointments on models for inflammatory dermatitis in mice. 2003 Arch. Dermatol. Res. pmid:12624780
Ito F et al. FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. 1999 Arch. Dermatol. Res. pmid:10367710
Lubaki LJ et al. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. 2010 Arch. Dermatol. Res. pmid:19547993
Eberlein-König B et al. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. 1997 Arch. Dermatol. Res. pmid:9373722
Hultsch T et al. Direct evidence that FK506 inhibition of FcepsilonRI-mediated exocytosis from RBL mast cells involves calcineurin. 1998 Arch. Dermatol. Res. pmid:9681677
García-García B et al. Frosch' surface microscopy score for the assessment of steroid-induced atrophy. 2014 Arch. Dermatol. Res. pmid:24402286
Paus R et al. Hair growth control by immunosuppression. 1996 Arch. Dermatol. Res. pmid:8818191
Furukawa F et al. FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. 1995 Arch. Dermatol. Res. pmid:7487142
Ockenfels HM et al. Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. 1995 Arch. Dermatol. Res. pmid:7541191
Yoon NY et al. Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model. 2015 Arch. Dermatol. Res. pmid:25786383
Hofmann M et al. Validation of Dermaphot(®) for the assessment of steroid-induced skin atrophy. 2013 Arch. Dermatol. Res. pmid:23242470
Toyota N et al. Effects of FK506 and cyclosporin A on proliferation, histamine release and phenotype of murine mast cells. 1996 Arch. Dermatol. Res. pmid:8844128
Engelhart K et al. In vitro reproduction of clinical hallmarks of eczematous dermatitis in organotypic skin models. 2005 Arch. Dermatol. Res. pmid:15952007
Hultsch T et al. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. 1998 Arch. Dermatol. Res. pmid:9808344
Lauerma AI et al. Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. 1994 Arch. Dermatol. Res. pmid:7526805
Hofman T et al. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. 2006 Arch. Dis. Child. pmid:16798785